{"entity":{"id":"daniel-von-hoff","kind":"person","name":"Daniel D. Von Hoff","aka":[],"tldr":"Led the MPACT trial of nab-paclitaxel plus gemcitabine and has run more first-in-human cancer trials than almost anyone.","summary":"Daniel Von Hoff (TGen and HonorHealth, Phoenix) was principal investigator of MPACT, which established gemcitabine plus nab-paclitaxel as a first-line standard in metastatic pancreatic cancer, and has led the early clinical development of many approved drugs including gemcitabine, irinotecan and vismodegib. He founded one of the largest phase 1 programmes in the United States and was a founding editor of Molecular Cancer Therapeutics.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Daniel_Von_Hoff","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Von%20Hoff%20DD%5BAuthor%5D%20pancreatic"}],"tags":["pancreatic","early-phase","drug-development"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["tgen"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Distinguished Professor, Translational Genomics Research Institute (TGen); Physician-in-Chief, HonorHealth Research Institute","institutionId":"tgen","specialisms":["Pancreatic cancer","Early drug development","Phase 1 trials","Precision oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Von%20Hoff%20DD%5BAuthor%5D%20pancreatic"}],"papers":[{"title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine (MPACT)","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1304369"},{"title":"Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial","journal":"JCO","year":2011,"doi":"10.1200/JCO.2011.36.5742"}]},"route":"/people/daniel-von-hoff/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"institution":[{"id":"tgen","kind":"institution","name":"Translational Genomics Research Institute (TGen)","route":"/institutions/tgen/"}],"paper":[{"id":"paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013","kind":"paper","name":"MPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer","route":"/key-papers/paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013/"},{"id":"paper-napoli-1-nanoliposomal-irinotecan-lancet-2016","kind":"paper","name":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","route":"/key-papers/paper-napoli-1-nanoliposomal-irinotecan-lancet-2016/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}],"trial":[{"id":"mpact","kind":"trial","name":"MPACT","route":"/trials/mpact/"}]}}